Kaposi's Sarcoma in Patients with Human Immunodeficiency Virus Infection in Taiwan

Background and purpose: Kaposi's sarcoma (KS) continues to occur in patients with human immunodeficiency virus (HIV) infection in the era of highly active antiretroviral therapy (HAART), and remains the most common HIV-associated malignancy. This retrospective study was conducted to describe the change in incidence and characteristics of HIV- associated KS in Taiwan. Methods: The medical records of patients with HIV infection who received a diagnosis of KS at the National Taiwan University Hospital between June 1994 and March 2008 were reviewed. Results: During the 14- year study period, 62 HIV-infected patients were diagnosed with KS, which included 40 definite diagnoses (64.5%) by pathology and 22 probable diagnoses (35.5%) ascertained by characteristic lesions, compatible clinical manifestations, and response to treatment. Most of the patients were men who have sex with men (MSM; n = 53; 85.5%). At the time of diagnosis of KS, the median CD4 count was 20 cells/mu L ( range, 1-371 cells/mu L). A considerable decline in the incidence of KS in HIV-infected patients since the introduction of HAART was demonstrated; in the pre- HAART era , 18 of 175 patients (10.3%; 95% confidence interval [CI], 6 .53 -15.75) developed KS, compared with 44 of 1615 patients in the HAART era ( 2.7%; 95% Cl, 2.03-3.65) [p < 0.0001]. The prognosis of HIV-infected patients with KS has improved since the introduction of HAART, as the mortality rate has declined from 77.8% in the pre-HAART era to 34.1% in the HAART era (p = 0.002). Conclusions: The incidence of KS in HIV- infected patients and the mortality rate of these patients significantly declined in the HAART era, although KS continued to occur in patients with advanced HIV infection